Rodolfo Diaz has joined ESTERN Medical CRO Life Sciences as our Director of Healthcare Life Sciences Business Development & Commercialization Strategy. In his role, Mr. Diaz will be based across the US North America, and Latin America, leading and executing healthcare growth strategies, partnerships, and commercialization for Pharmaceutical, Biotechs, Medical Device / MedTech, and CRO initiatives within the clinical R&D corporate pipeline.

Mr. Diaz is a Biomedical Engineer with a Pre-Med degree from the Ibero-American University (UIA). With over 25 years of experience in life science healthcare, he has worked for global companies such as Siemens Healthineers, Bayer Pharmaceuticals, Schering Ag Pharma, and Medrad Inc. as a senior executive in the US and LATAM regions. Mr. Diaz has played a pivotal role in structuring the first Latin American Medrad, Inc. subsidiary, now known as Bayer Radiology Pharma Solutions, from proof of concept to product launches, and the strategic consolidation of business development and marketing teams in LATAM and the US.

Throughout his career, Mr. Diaz has developed strong business acumen and experience in clinical management, enabling him to establish effective work management for international teams focused on corporate profitability, product lifecycle management, and building strong relationships with business partners, clients, sponsors, and end-users for commercialization.

In his past and present professional responsibilities, Mr. Diaz has been involved in various medical modalities such as Cardiac Disease, Central Nervous System, Ophthalmology, Oncology, Liver and Kidney Disease, as well as Magnetic Resonance Imaging (MRI), Computed Tomography Imaging (CT), Cardiac and Peripheral Interventional Diagnostic and Therapeutic, Nuclear Medicine Imaging, and imaging management PACS (Picture Archiving & Communication Systems), and RIS Radiology information systems. He brings this broad international expertise and knowledge to ESTERN Medical CRO Life Sciences.

Mr. Diaz offers a balanced perspective from Pharmaceutical, Medical Device, CRO, Life Sciences, and Sponsor viewpoints, across the R&D clinical drug development spectrum, from early-phase to late-phase clinical trials.